Developmental medicine and child neurology · 2005
DOPA-sensitive dystonia-plus syndrome.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Casseron Wilfrid, Genton Pierre
Аннотация
We report on two sisters with a childhood-onset form of predominantly axial dystonia with marked diurnal fluctuations. Onset of clinical features was at approximately 6 years of age. Associated features included marked fatigue, slight facial dysmorphism, short stature, obesity, and learning disability*. Dystonia and fatigue responded to 3,4-dihydroxyphenylalanine (DOPA) therapy, with recurrence of symptoms upon withdrawal; the efficacy has been maintained over 7 years. Other symptoms were not influenced. There was no other case in the family (which included an older, healthy brother), except for non-specific fatigue without dystonia in the mother, and there was no significant family history except for obesity on the father's side. These observations are discussed in relation to the classical descriptions of Segawa syndrome, and to more recent reports of childhood onset, age-related, and transient benign paroxysmal tonic upgaze and ataxia. The combination of symptoms, their sensitivity to DOPA, and their persistence throughout childhood constitute, to our knowledge, a new clinical entity, which we propose to categorize as a DOPA-sensitive dystonia-plus syndrome.
Предметные рубрики MeSH
AdolescentBenserazideBrainChildChild Behavior DisordersChild, PreschoolCraniofacial AbnormalitiesDNA Mutational AnalysisDevelopmental DisabilitiesDiagnosis, DifferentialDihydroxyphenylalanineDopamine AgentsDose-Response Relationship, DrugDrug Therapy, CombinationDystonic DisordersFatigueFemaleFollow-Up StudiesGTP CyclohydrolaseGenotypeHumansLearning DisabilitiesMagnetic Resonance ImagingNeurologic ExaminationPedigreePhenotypeResidential TreatmentStatistics as TopicSubstance Withdrawal SyndromeTreatment Outcome